Nov 12
GTBP · GT Biopharma, Inc.
$3.72
-0.12 (-3.13%)
At close · Nov 13
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.71M
Shares
1.80M
Volume · Nov 13
66.92K
Avg daily vol (48 sessions)
89.87K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.72
Open$3.85
Day$3.60–4.11
52W close$3.72–23.03
Avg vol 30d63K
Short int246K · 13.7% of shares · 3.2d
Short vol42%
Last earningsJun 30, 2021
DataJan 2020–Nov 2026
Filing10-Q · Aug 14
Up next
Date not confirmed
Latest documents
2026
Oct 13
Proxy statement
DEF 14A
Proxy statement
GT Biopharma will ask stockholders on November 11, 2026 to eliminate obsolete preferred-stock charter provisions, increase authorized common stock from 25,000,000 to 250,000,000, approve issuance of 19.99% or more of outstanding shares, and authorize meeting adjournment.
Oct 9
Registration statement
S-1
Registration statement
GT Biopharma registers up to 13,502,835 common shares for selling-stockholder resale; it will receive no proceeds. The company also disclosed substantial doubt about its ability to continue as a going concern.
Oct 2
Proxy statement
PRE 14A
Proxy statement
GT Biopharma seeks approval at its November 11, 2026 special meeting to increase authorized Common Stock from 25,000,000 to 250,000,000 and issue 19.99% or more of outstanding shares under the Securities Purchase Agreement. The Board recommends FOR each proposal.
Sep 25
Current report
8-K
Events of Sep 22
Other events
GT Biopharma received Nasdaq notice on September 22, 2026 that its common stock regained compliance with the minimum bid price requirement after maintaining a closing bid price above $1.00 per share for at least ten consecutive business days.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$4.76M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 2,916.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,300.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
13.7%
Latest settlement · 3.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 19.3 · elevated
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
−40%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−47%
trailing
6-month return
−66%
trailing
YTD return
−81%
this year
Relative strength
−67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $9 — 200d above 50d
Institutional flow
Distributing
50 of 59 funds reported for Sep 30 · net -23.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.66% of shares out · ▼ -11.6% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
+4%
Y/Y
Free cash flow
$-12.9M
Quant / Vol
risk profile
Volatility
124%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
14.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
−40%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $9 — 200d above 50d
Institutional flow
Distributing
50 of 59 funds reported for Sep 30 · net -23.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.66% of shares out · ▼ -11.6% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $4 · 0%
Range high $23
vs 200-day avg -59%
vs 50-day avg -40%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GTBP
this stock
GT Biopharma, Inc.
|
$6.71M | — | — | — | 13.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GTBP | -15.8% | -47.1% | -66.2% | -30.1% | -81.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -18.4% | -45.9% | -66.7% | -29.9% | -91.7% |
Key facts
CIK
109657
CUSIP
36254L407
13F (30d)
26 filings
18 filers
Visit website
Investor relations